Işıl Erdoğan ÖZÜNAL, Emrah KILIÇASLAN, Muhammet Kürşat KAPTAN
Cerrahpaşa Medical Journal - 2026;50(1):1-5
Objective: Pretreatment serum 25-hydroxyvitamin D (25(OH)D) levels in Hodgkin Lymphoma (HL) patients were investigated. Methods: Serum 25(OH)D levels in newly diagnosed HL patients were compared with those of a non-cancer control group. None of the participants were taking vitamin D supplements before the study. Results: A total of 120 individuals were enrolled (60 HL patients and 60 controls). The mean 25(OH)D level was 11 +/- 8.52 µg/L in the patient group and 26.85 +/- 10.52 µg/L in the control group (P < .005). Females had lower 25(OH)D levels in the patient group (8.93 +/- 3.7 µg/L vs. 14.76 +/- 9.4 µg/L, P = .001). The mean 25(OH)D level did not differ according to sex in the control group (28.4 +/- 9.6 µg/L in males vs. 24.4 +/- 11.9 µg/L in females, P = .17). Thirty-one (51.7%) patients had advanced-stage disease. The mean 25(OH)D level was lower in patients with advanced-stage disease (10.7 +/- 4.22 µg/L vs. 15.48 +/- 11.02 µg/L, P = .035). Patients with an initial presentation of B symptoms, bulky disease, or splenic involvement had lower 25(OH)D levels (P = .025, .01, and .009, respectively). Progression-free survival was shorter (62 vs. 108 months, P = .002) in patients with severe deficiency (<10 µg/L). Conclusion: Pretreatment vitamin D levels are low in HL and decrease as the disease burden increases. Progression-free survival was shorter in patients with severe deficiency.
